A clinical approach to the use of methotrexate for sarcoidosis

Robert P Baughman, Elyse E Lower

The management of patients with sarcoidosis has been the subject of many papers in this\textsuperscript{1} and other journals.\textsuperscript{2–9} The large number of papers are, in part, because of the difficulty in defining who should be treated for this disease and with what. The most commonly used pharmaceutical class for sarcoidosis has been corticosteroids, both topically and systemically.\textsuperscript{10} The use of systemic steroids for sarcoidosis was the subject of a trial by the British Thoracic Society\textsuperscript{11} which concluded that there were some patients who required no treatment and some who would need immediate treatment because of the severity of the disease. In between was a group of patients with persistent disease who appeared to benefit from treatment with corticosteroids. One of the points made was that some patients needed treatment for long periods of time.

The term “chronic sarcoidosis” has been used by Dr Geraint James to describe patients with disease for more than two years.\textsuperscript{12} He noted that some features of sarcoidosis such as lupus pernio and neurological disease were associated with a low rate of remission, while other features such as erythema nodosum were associated with a high resolution rate by two years. Several other manifestations of the disease have been associated with chronic disease: bone cysts, cor pulmonale, pulmonary fibrosis,\textsuperscript{13} and nephrolithiasis.\textsuperscript{14} Based on the type and duration of symptoms one can classify patients as acute or chronic.\textsuperscript{15} A third group is also evident—namely, those who are refractory to corticosteroid therapy. This includes some neurosarcoidosis patients, patients who develop organ failure, and those who die despite corticosteroid treatment.\textsuperscript{16} Treatment for sarcoidosis is often dependent on the patient’s own manifestation. A patient with anterior uveitis may be a candidate for topical steroids alone, but a patient with neurological disease may need chronic high dose corticosteroids to control the disease.\textsuperscript{17} Patients in the chronic category have been interested for years in taking alternatives to corticosteroids. Fortunately, a group of agents has been used as steroid sparing agents in sarcoidosis.\textsuperscript{18–21} We will discuss the use of one of these, methotrexate.

The first report of methotrexate in the treatment of sarcoidosis was over 30 years ago.\textsuperscript{22} The drug was initially used for chronic cases. Although it was sometimes effective, clinicians would usually limit treatment to six months because of concerns about the toxic effects of the agent, particularly bone marrow suppression and hepatotoxicity.\textsuperscript{23} Methotrexate has been used widely in rheumatoid arthritis and experience with the agent in both adults and children has demonstrated its relative safety.\textsuperscript{18–22} In these patients the toxicity from methotrexate was predictable and guidelines for monitoring the agent became available.\textsuperscript{23}

We became interested in the use of methotrexate for sarcoidosis over 10 years ago. The original patients had been on corticosteroids for many years (range 2–23 years, median 5 years) and wished to try an alternative agent.\textsuperscript{24} In some cases we had patients who refused to take prednisone again despite advancing disease. In our first 15 patients it was clear that methotrexate was an agent that took some time to be effective. For the majority of patients objective evidence of response to treatment could take as long as six months, although subjective improvement was sometimes seen sooner. Thus, the recommendation that the drug should be withdrawn after six months meant that patients would be perceived as not responding simply because they had not received the drug for sufficient time.

Because of this clinical response we studied the inflammatory response to methotrexate compared with prednisone in patients with sarcoidosis.\textsuperscript{25} In sarcoidosis the researcher has the unique opportunity to examine the inflammatory cells in the organ affected by the disease. Bronchoalveolar lavage (BAL) has provided a large amount of information regarding interstitial lung diseases, especially sarcoidosis.\textsuperscript{26} The BAL fluid of a patient with active sarcoidosis usually contains an increased percentage of T lymphocytes, usually CD4+ cells.\textsuperscript{27} In addition, the alveolar macrophages retrieved by BAL from patients with sarcoidosis are activated and release various products including hydrogen peroxide and tumour necrosis factor (TNF).\textsuperscript{27,28} In our study patients with active sarcoidosis were treated with either prednisone or methotrexate and the clinical and inflammatory response was measured. Patients were treated for at least six months with either agent. There was a significant improvement in the vital capacity over this time period for both drugs. The increased number of lymphocytes found in the BAL fluid of patients with active sarcoidosis fell significantly with treatment with either agent, and the CD4:CD8 ratio became closer to normal (table 1). The spontaneous release of TNF was again seen from the alveolar macrophages retrieved by BAL in patients with active sarcoidosis. This also fell with treatment in both the prednisone and methotrexate groups.\textsuperscript{29} This study was neither blinded nor randomised. Some patients treated with methotrexate also received low dose corticosteroids.

Several studies have demonstrated the value of methotrexate in patients with refractory disease. These are summarised in table 2. Many of
these reports concerned a few cases with chronic disease. The most common manifestations include skin disease, especially lupus pernio. The response rate for skin disease appears high. The patients with lung disease are less likely to respond, with about half of patients reporting some response. One difficulty with these case reports is the fact that one does not have a sense of how many cases did not respond to treatment. One group reported on their use of methotrexate with both corticosteroids and cyclosporin. Although there was a good clinical response, it was not clear how much the methotrexate contributed to the effectiveness. It was the best tolerated of the three drugs given.

In a study of paediatric sarcoidosis, children received methotrexate following a strict protocol. Corticosteroids were used for the first weeks only in six of seven cases. They were treated with methotrexate for one year and the clinical response was scored using a composite of the various symptoms encountered. The methotrexate was associated with a significant improvement in the clinical score compared with placebo alone. One criticism of this study is the use of a clinical score rather than objective measurements. However, most patients have a multisystem disease, with many of the symptoms being subjective. These include fatigue, myalgias, and pain, and are true symptoms for the patient, representing indications for treatment.

We have treated a large number of patients with methotrexate. Table 3 summarises our experience with the clinical response in 50 patients treated for at least two years. It is clear that not all patients will respond to methotrexate. In some patients we did not see a response but were able to reduce the dosage of prednisone. Our overall response rate in that study was 66%. In a follow up report of 209 patients treated for at least six months with methotrexate 52% appeared to be in remission and 16% were stable on methotrexate with or without low dose prednisone. In a separate report patients with neurosarcoidosis who were treated with various agents were analysed. Methotrexate was given to 28 of these patients and a response was seen in 61%.

The long standing use of methotrexate for malignancy, rheumatoid arthritis, and psoriasis has given an understanding of the toxicity of the drug. There appear to be four major categories of toxicity: haematological, gastrointestinal, pulmonary, and hepatic; there does not seem to be a particular toxicity in sarcoidosis patients that has not been reported in the other groups, although the frequency of haematological and hepatic toxicity may be higher in sarcoidosis patients because of underlying organ involvement.

Sarcoidosis can affect the bone marrow. The toxicity can be the result of mechanical disruption of the marrow by granulomas as well as an indirect effect from the various cytokines released. Serial studies of patients with sarcoidosis have shown one or more haematological abnormalities in over half of the cases. Lymphopenia is the most common abnormality. Significant anaemia is seen in 20% of cases and leukopenia occurs in 10% of cases. The reduction of the neutrophil count below 3000 cells/cm³ can lead to problems when giving a bone marrow suppressive agent such as methotrexate. However, monitoring of the white blood count on a regular basis is usually sufficient to avoid this complication.

Methotrexate can cause mucositis as well as nausea and even vomiting. This is a dose dependent effect, although there is enough variation in patient sensitivity that one can see toxicity even at the low doses used for sarcoidosis. Folate is a useful antidote for the toxicity of methotrexate and does not appear to inhibit the benefit of the drug. In one study of patients with rheumatoid arthritis the routine use of folate significantly reduced toxicity from methotrexate. In some patients we did not see a response but were able to reduce the dosage of prednisone. Our overall response rate in that study was 66%. In a follow up report of 209 patients treated for at least six months with methotrexate 52% appeared to be in remission and 16% were stable on methotrexate with or without low dose prednisone. In a separate report patients with neurosarcoidosis who were treated with various agents were analysed. Methotrexate was given to 28 of these patients and a response was seen in 61%.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients treated</th>
<th>Response</th>
<th>Other drugs</th>
<th>Major organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lacher et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered off</td>
<td>Lungs, skin</td>
</tr>
<tr>
<td>Vein et al.</td>
<td>16</td>
<td>12/16 with skin, 3/4 with eye</td>
<td>None</td>
<td>Skin, lungs, eye</td>
</tr>
<tr>
<td>Fenton et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered</td>
<td>Nasal, skin</td>
</tr>
<tr>
<td>Lower et al.</td>
<td>15</td>
<td>Lungs in 9/15, skin 3/3, liver 2/2</td>
<td>Prednisone tapered in 9/10</td>
<td>Lung, liver, skin</td>
</tr>
<tr>
<td>Soriano et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered</td>
<td>Intrallesional corticosteroids</td>
</tr>
<tr>
<td>Chittock et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered</td>
<td>Skin</td>
</tr>
<tr>
<td>Henderson et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered</td>
<td>Laryngeal, cutaneous</td>
</tr>
<tr>
<td>Rajendran et al.</td>
<td>12</td>
<td>Excellent 7, good 4</td>
<td>Four good responders on prednisone</td>
<td>Skin</td>
</tr>
<tr>
<td>Lower et al.</td>
<td>50</td>
<td>Lung in 17/30, skin in 16/17, eye in 2/2</td>
<td>Prednisone tapered in 20/33, 16 tapered off</td>
<td>Lungs, skin, eyes</td>
</tr>
<tr>
<td>Lennarson et al.</td>
<td>1</td>
<td>1</td>
<td>Prednisone tapered</td>
<td>Erysplastic, liver</td>
</tr>
<tr>
<td>Kaye et al.</td>
<td>4</td>
<td>4</td>
<td>Prednisone tapered in 4 of 4</td>
<td>Neurological</td>
</tr>
<tr>
<td>Agbegbu et al.</td>
<td>3</td>
<td>3</td>
<td>Prednisone tapered</td>
<td>Lungs, skin, arthritis</td>
</tr>
<tr>
<td>Pia et al.</td>
<td>11</td>
<td>11</td>
<td>Prednisone tapered</td>
<td>Skin, joints, eye, lung</td>
</tr>
<tr>
<td>Gedalia et al.</td>
<td>7</td>
<td>Complete 5, partial 1</td>
<td>Prednisone for four weeks only in 6 of 7</td>
<td>Neurological</td>
</tr>
<tr>
<td>Lower et al.</td>
<td>28</td>
<td>17</td>
<td>Prednisone tapered in all</td>
<td>Cardiac</td>
</tr>
<tr>
<td>Morishita et al.</td>
<td>9</td>
<td>5</td>
<td>Prednisone</td>
<td></td>
</tr>
</tbody>
</table>
methotrexate. We do not usually start with methotrexate in 50 patients with sarcoidosis. Table 3 Response rate to prolonged treatment with methotrexate use is hepatotoxicity. All three cases had cough associated with methotrexate pulmonary toxicity. Since sarcoidosis affects the lung in 90% of patients, there may be confusion regarding pulmonary toxicity. Fortunately, pulmonary toxicity from methotrexate is usually dose dependent, occurring after months to years of treatment. Patients with pulmonary sarcoidosis are usually being followed with serial chest radiographs and pulmonary function studies. A worsening of pulmonary symptoms in a patient who has been on methotrexate warrants evaluation. If no other cause such as infection can be found, consideration should be given to stopping the drug and seeing if symptoms are relieved. In over 200 patients treated we have seen three patients with possible methotrexate pulmonary toxicity. All three cases had cough associated with the drug that resolved with discontinuation of the drug and treatment with corticosteroids. All patients developed cough again when rechallenged with methotrexate. None of the cases developed definite worsening of their pulmonary function or chest radiograph. We presume that the patients were treated prior to the development of a complete hypersensitivity pneumonitis. However, cough and obstructive disease have been reported as a distinct pulmonary toxicity from methotrexate.

The major toxicity associated with long term methotrexate use is hepatotoxicity. This problem has been well appreciated and guidelines have been established in patients taking chronic methotrexate. The most conservative is to re-evaluate the patient after each gram of cumulative dose (approximately every two years). If the patient remains stable, nothing further is required. If symptoms occur the drug is reinstituted to determine whether the patient will respond to methotrexate. If the patient improves (usually within two months) then a liver biopsy is performed to determine whether the patient can remain on the drug. If methotrexate toxicity is seen the drug is withdrawn. Of the first 90 liver biopsy specimens we have taken, nine had evidence of methotrexate toxicity and the drug was withdrawn in all cases. None went on to develop irreversible liver damage.

Given the concerns about the hepatic toxicity of methotrexate, the question is why not perform liver function tests? We do measure liver function on a regular basis but find that liver toxicity is not easily predicted on the basis of any of the liver function tests. Figure 1 summarises the results of liver function tests in 27 patients undergoing liver biopsy after two or more years of treatment with methotrexate. The biopsy results of nine patients with methotrexate toxicity are compared with those of nine patients with sarcoidosis in their liver and nine patients with neither sarcoidosis nor methotrexate toxicity. The highest abnormal liver function test result for each patient in each group is shown. As can be seen, there was considerable overlap between the three groups. Thus, no liver function test abnormality predicted disease. If a patient develops marked worsening of liver function then methotrexate should be evaluated. The presence of liver disease due to sarcoidosis is not a contraindication to treatment with methotrexate. In our patients with liver involvement from sarcoidosis we have found that methotrexate may improve the liver function tests. Methotrexate has also been used for idiopathic granulomatous hepatitis.

Other toxicities should be considered with methotrexate use. The drug is clearly teratogenic and has been shown to cause spontaneous abortions in early pregnancies. Patients (both male and female) should be advised to use adequate birth control for up to six months after discontinuation of the drug. Although there is some concern that methotrexate can cause malignancy, several large series have failed to show an increase in malignancy in patients treated with methotrexate and followed for up to 10 years. This type of long term carcinogenic study has not yet been reported in patients with sarcoidosis.

### Table 3 Response rate to prolonged treatment with methotrexate in 50 patients with sarcoidosis

<table>
<thead>
<tr>
<th>Organ involved*</th>
<th>No. with involvement</th>
<th>No. (%) responding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>47</td>
<td>22 (47)</td>
</tr>
<tr>
<td>Skin</td>
<td>17</td>
<td>16 (94)</td>
</tr>
<tr>
<td>Liver</td>
<td>7</td>
<td>3 (43)</td>
</tr>
<tr>
<td>Nervous system</td>
<td>7</td>
<td>3 (43)</td>
</tr>
<tr>
<td>Joints</td>
<td>3</td>
<td>3 (100)</td>
</tr>
<tr>
<td>Any organ</td>
<td>50</td>
<td>33 (66)</td>
</tr>
</tbody>
</table>

*Patients could have more than one organ involved.
A clinical approach to the use of methotrexate for sarcoidosis

Given the above information, our approach to the use of methotrexate in patients with sarcoidosis is summarised in Fig 2. The typical patient has been on corticosteroids for more than a year, usually two. The patient who can be controlled with low doses of corticosteroids of less than 10 mg/day prednisone or its equivalent is usually not considered a candidate for treatment with methotrexate. Some patients will refuse to continue corticosteroids at any dose, and they are also candidates for methotrexate. Rarely, patients with severe problems with corticosteroids and systemic symptoms associated with prolonged disease will be treated with methotrexate. Patients are usually started on 10 mg per week of the drug orally. Intramuscular administration may be cheaper in some situations, but the dose should be reduced by half. The patient is seen every 4–6 weeks.

The complete blood count is checked for white blood cells and platelet numbers. If the white blood cells drop below 3000/mm³ then we reduce the dose by half. In patients who are neutropenic to begin with, the starting dose is reduced and the patient monitored to be sure that the absolute neutrophil count does not go below 1000 cells/mm³. The platelets may also decrease with treatment but will respond to lowering the dosage.

Methotrexate is excreted by the kidney and the serum creatinine levels should therefore be monitored. A concern has been raised in the rheumatology literature regarding the use of non-steroidal agents with methotrexate. Since this is a common situation in patients with chronic pain, it is not a trivial problem. However, the drug interaction appears to be caused by the effect of the non-steroidal agents on renal function, further emphasising the need for routine renal function studies. The monitoring of liver function has been alluded to earlier. We have found occasional transient increases in liver enzymes if blood is sampled the day after administration of methotrexate. We therefore try to measure liver function before the next dosage of the drug.

For the first six months of treatment with methotrexate the drug seems to have little effect on the disease. Patients who are on corticosteroids at the start of methotrexate treatment are usually maintained on the same dose until six months have passed. At that time, tapering of the corticosteroids usually begins. In most, but not all, patients the corticosteroids can be discontinued. The patient continues on treatment for two years, at which time methotrexate is withdrawn as discussed above. About 20% of patients will remain stable. For those who become symptomatic again, methotrexate is reinstituted as before. Patients will usually improve within two months, or longer if they have been off the drug for a longer period. If they do improve then a liver biopsy sample is taken. Our experience is that 10% of patients will have changes consistent with methotrexate toxicity and the drug is therefore withdrawn. For the remainder methotrexate can be given for two more years until the next liver biopsy sample is taken. We have several patients from whom three or more liver biopsy samples have been taken who have shown no evidence of methotrexate toxicity.

Future studies in patients with sarcoidosis may help to clarify the role of the drug. Since methotrexate is well tolerated by patients a double blind, randomised trial comparing methotrexate with placebo can be performed. A randomised, double blind study comparing methotrexate with placebo was carried out in patients with acute disease and showed a modest steroid sparing effect. However, the more important role of methotrexate appears to be for chronic disease so future research should include a study of methotrexate versus placebo in patients with chronic disease. Another important question is whether methotrexate, azathioprine, or hydroxychloroquine are equally steroid sparing. Finally, it is not clear whether combinations of immunosuppressants may not be better than any single agent.

In conclusion, methotrexate represents an acceptable alternative to corticosteroids in patients with sarcoidosis. This drug should be considered in the patient with chronic or refractory disease. The acceptance rate among patients is high, reflecting its better toxicity profile compared with prednisone. It is not the perfect agent and is certainly not for every patient with sarcoidosis. However, it can be useful for many patients.

Supported in part by National Institutes of Health grant NO1-HR-56069.

A clinical approach to the use of methotrexate for sarcoidosis

Robert P Baughman and Elyse E Lower

Thorax 1999 54: 742-746
doi: 10.1136/thx.54.8.742

Updated information and services can be found at:
http://thorax.bmj.com/content/54/8/742

These include:

References
This article cites 55 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/54/8/742#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Chemotherapy (183)
Inflammation (1020)
Interstitial lung disease (559)
Occupational and environmental medicine (128)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/